To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024.

Bill: 118-hr-2297
Sponsor: full_name: Rep. Biggs, Andy [R-AZ-5]
Introduced: 2023-03-29
Policy area: Health
Latest action: action_date: 2023-04-07
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2023-03-29
action_desc: Introduced in House
text: <p>This bill limits FY2024 funding for the Food and Drug Administration (FDA) Innovation Account, which the FDA uses to implement provisions of the 21st Century Cures Act relating to the development of medical products.</p>

tv_txt: I 118th CONGRESS 1st Session H. R. 2297 IN THE HOUSE OF REPRESENTATIVES March 29, 2023 Mr. Biggs (for himself, Mr. Rosendale , Mr. Gaetz , Mr. Good of Virginia , Mr. Roy , and Mr. Crane ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024.

1. Limitation on availability of funds for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024 Notwithstanding any other provision of the law, amounts authorized to be appropriated or otherwise available for Related Agency and Food and Drug Administration, FDA Innovation Account, Cures Act for fiscal year 2024 may not exceed $50,000,000.